{"name":"IC TARGETS AS","slug":"ic-targets-as","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPakZzbEotZ3JFNk9TbXdaWFJWMjJHakUwd3dsc0JTT0lfeXlYaEhtWndmazRnT0doVjRfejE1MEtLTVhlVERvUmhyTHFDa3BXeXpuS2dzUi1lNnZYYU5VSGc0SmhSUjNFaHlQRl9BWTZuNjFqUjcweTQwQ2lLaV9kSHNBTEVvQUJObnY2SzQxTm15U1dQOVJQWEdCWjJ2Zw?oc=5","date":"2026-01-17","type":"regulatory","source":"24/7 Wall St.","summary":"Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - 24/7 Wall St.","headline":"Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQZ1I2MHp0dG5FLTV4QVJRZHdiNThVV2lXNW5uanJIa3pUSmdKZnhxTTJwU2hSRTZrZFQ2ZE5HZTFyajBsNFpEODdqdVNpVk9oMkp5aHprMF9COFFOUld5aWJzWFp2OVpZVmNpVERhNi1yRTc1c0JVNXFGUzdrdm5WTWZnNTBIcF9TbHloZEViUDR6dlFBZzItS1k0QUdDSU81UDBTX3o5Q0p5MTkxRXVZbmlVMmVhZw?oc=5","date":"2025-09-10","type":"pipeline","source":"Urology Times","summary":"Sunobinop shows promising efficacy in interstitial cystitis/bladder pain syndrome - Urology Times","headline":"Sunobinop shows promising efficacy in interstitial cystitis/bladder pain syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOQkdhUjVNeF9XZE1NOEtHZVVyMVQyb2dybl90dE9iSHVfOWQzQURjWEJpbk10WU1HalVZVXlQREM0cDB2ODRUblhnZWJ3LWRIeEFCNzR2dllVdzJSeEE0WEtrM19hNXRZQ3QtZTdEWS1kZmtlTUtnUmw3OWdOVWxsUEVnb1hOd0NuLW1HLVUzbGZUYU9neGd6OGZ2RTlxeVZNZUt6aEpvcXdCcW1SQ2FSdldiNnZUTzY3eXZaSWVPNFNMOC1ONjJHUnBCdmNJZGVJVUJ1aGxPY3IwZkFLV2VaSkp2OFl4RHhpaFVneURsU1hCamFGM1FsSVp6Q2RGc0xCbFUzNmRGS3hubE5HdVl1Ty1LUVViTTBENmNGcHNXQXJfNDZVcDB4M2hvRlhnd1dMTzNaZEQxcXl1X2oxN3JNNlNn?oc=5","date":"2025-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Apellis Announces FDA Acceptance and Priority Review of the - GlobeNewswire","headline":"Apellis Announces FDA Acceptance and Priority Review of the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPLXRjN0s3Y21LN0YzdTRzYnhSbHZiUlpXWVFibjdlVGo1N3dQbm9jbTdkanRFNEpxNDZpUkdINDVWYS1rSkJJRUM3RHdheDJMRWdvbzdkN1dDT1VZTmVlVHJFd0h6MFlZSWZESlpySDJmVS1faHg5ZHk1dkpBSF9YZVIxTzliaklyNjFqNjF4ODUtTjB4M0hITGhHVENQdDF4Vm56UlVqTlRQM0JJdzNRUQ?oc=5","date":"2025-03-11","type":"trial","source":"Urology Times","summary":"Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome - Urology Times","headline":"Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVzZfOE5ZU1QzUVZuR1dDcE9vcW5rRzNPVkk4VHNMbkstcXhKR1RCQ2ZtVXp3MkZNR1NEeWJvTlBVd2t2aUF3dkZDRUpPUHF4V3ZPZVQ0RndTYTdfUG9lWkluYjhXcVdWNkloOUhpNjZqRUNtR3poUFBRWFo5MGtaV3dfdFlYNjl1Q3lRNlRQVWZUNDVaREtnZDVMTHNpX19YVWZteFFPdHUtUHAzWnR5dm02cDZ6LUtrZ3RkbzNScHo?oc=5","date":"2024-10-28","type":"regulatory","source":"Fierce Pharma","summary":"Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease - Fierce Pharma","headline":"Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE96NjFLbnREQ0pBMV81enFMdnRNbEtxa1ZXWDAxQ3ZjdnVCc0tFQXlRVjQ5Qkd0QnNybVFUX2s4ZTFYRzlOVC02RXloZkRLM3VzMzUxZ2hEQnVBd3hPV1BB?oc=5","date":"2024-09-19","type":"pipeline","source":"nature.com","summary":"Purine nucleoside phosphorylase as a target for the treatment of interstitial cystitis/bladder pain syndrome with and without Hunner lesions - nature.com","headline":"Purine nucleoside phosphorylase as a target for the treatment of interstitial cystitis/bladder pain syndrome with and wi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQRDlKemFQNVZ3SGZNTDlFbzF6OUhFb2pYZnAzVElPa0I2a3BBNDVMUnlZcFFHdTVhZm4zdUVtcmQ0SVVLSVR6RFoxdVVSX3M3V293QUwwMXRYYVQ0MmhFcDdEMW9USTIwTy1QcWRnVUtmTWpyZFRtOTAwQms0UExITUxtVlJTTEdwTHE5M2Utb0ZHbHlzckl1Vm1rT3FFZlFNRW9tTlVNb2ZyZXlMMU9JWXZPaw?oc=5","date":"2024-08-14","type":"trial","source":"PMLiVE","summary":"Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study - PMLiVE","headline":"Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNbmIyRjVJMENNUzB2M0xydXEzRjhlYXMyM1A2QmxVcEluU1pmZFRVX0RTd1NYLVBUNC1MS1lLUTBwbDRLU28tSUpXNm9ab2pRNVNHVDdJUktaU0lGMkF1TzZVZjllc3pFTlVxLUtmdDB3Rm4wMVdIZzE1emEwelVtUjdjWjBlN2xXNXZYb0JuSQ?oc=5","date":"2024-07-01","type":"pipeline","source":"Frontiers","summary":"Urea-based anticancer agents. Exploring 100-years of research with an eye to the future - Frontiers","headline":"Urea-based anticancer agents. Exploring 100-years of research with an eye to the future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOVRmbFRHSDk5YUt3b0dVZWJ0TWJPUDRjbktEaGw5X3hKbWxBVHo2RmFLaTNPNzJxeGRjQkRROUJfdlpzR2FUS1h6NUQ2b2ZyVGhJT01kb0hNaFBpemNuNnJLbVV5aTlpOXVjbFQ1VURkVzhLVm5YbGM1VEpxbmRCdWh2ajJ1LVU0Ql90VDVTaG1DRTZ4XzdwdW9jOGZSVVJSeG1wMmxTd1JXVmpzTjZQVm41NU9GZjZudEVHdlF1YTRmWnc1aEp2YkRLbTVteDhy?oc=5","date":"2022-10-20","type":"pipeline","source":"iqvia.com","summary":"Five Things to Know about Using NBRx in your Incentive Compensation (IC) Plan - iqvia.com","headline":"Five Things to Know about Using NBRx in your Incentive Compensation (IC) Plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPYllpQzlISTZlNkZBRHRWblhyRHgxRlNZcE5OUkxBYzhGUUxuaFJSbjA3VXNoRTJob28wM2RKeE5Vc2tIS2lJZWJCUWpYUE82YzloLXoxYkxWYzM3R3dIWWh5bHBqX3VSR1NuRUdoRE9Hb3h5WG5tcWZmMk9Qd1R4b05fNUU?oc=5","date":"2021-03-22","type":"trial","source":"Ophthalmology Times Europe","summary":"Study targets strategies for CI-DMO - Ophthalmology Times Europe","headline":"Study targets strategies for CI-DMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPemRZejNHbEQ1Rjc2Qkt2ekVhOWkxQkRxcFdJRExUQkRzNFEyTWIzdXpFc3ZVWXNUT2J6eHE0Z3hOM3FPVmhZN0VsbndBOGdrRlk0Mm9qcWVxazlNM3NnaWRRZDdQX0VVMHZ3Q3QwY1pOUWM0X3oyblVLMlVwOTJBaw?oc=5","date":"2021-02-15","type":"trial","source":"Ophthalmology Times","summary":"Study targets strategies for CI-DME - Ophthalmology Times","headline":"Study targets strategies for CI-DME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE54T3hMTC1QY1c2OXN0Vk1OMUxvMkpCTy1xNk9mWE1xSTVxd1pOQU5pRkdickJpVzU5VGp5MG1xSXYxZk1qRXVJMEZURzIzWVdOQXM2WFlHUHhUOUFlTTg0?oc=5","date":"2020-09-01","type":"pipeline","source":"nature.com","summary":"Novel immunotherapies to combine with PD-1/PD-L1 treatment - nature.com","headline":"Novel immunotherapies to combine with PD-1/PD-L1 treatment","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}